Skip to main content
Clinical Trials/NCT02735837
NCT02735837
Completed
Phase 2

The Effect of Non-Surgical Periodontal Therapy With Adjunctive Topical Doxycycline Gel on HbA1c in Patients With Type 2 Diabetes Mellitus (DM):A Randomized, Clinical Trial

Amirhossein Farahmand0 sites24 target enrollmentJanuary 2015

Overview

Phase
Phase 2
Intervention
Doxycycline Group
Conditions
Diabetes Mellitus With Periodontal Disease
Sponsor
Amirhossein Farahmand
Enrollment
24
Primary Endpoint
Periodontal pocket
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Aim:

The purpose of this study is to investigate the effect of nonsurgical periodontal therapy plus subgingivally doxycycline gel 3% on glycemic control in type 2 diabetes mellitus (type 2 DM) patients who have periodontitis.

Materials and methods:

A total of 24 type 2 DM patients with periodontitis will be selected for the study, and randomly divided into two equal groups,who are at least 35 years of age and 16 teeth and type II diabetes are (at least the last 3 months of diagnosis of diabetes and its FBS More than 110 have), and also with periodontal disease are chronic moderate (at least in three areas Attachment level to a depth of 3-4 mm maxillary or mandibular been confirmed by clinical examination and radiographic signs are being); Takes place. The initial HbA1c Patients should be between 7-9 percent over the past three months has changed his medication also found the necessary explanations on how to do that consent, Plaque index (PI) by Loe & Silness, bleeding on probing (BOP) based on Carter and Barnes (if any bleeding number 1 and its absence is 0), probing depth (PD) and clinical attachment levels (CAL) were recorded. "Group 1": (12 patients) was treated with oral hygiene instruction, scaling and root planing, and doxycycline gel for 15 days; and "Group 2": (12 patients) has the same treatment but with placebo gel, After 12 weeks their periodontal condition and Fasting blood sugar (FBS), glycated hemoglobin (HbA1c) level, will be reevaluated.

Detailed Description

Doxycycline downregulates the activity of matrix metalloproteinases (MMPs), key destructive enzymes in periodontal disease

Registry
clinicaltrials.gov
Start Date
January 2015
End Date
April 2016
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Amirhossein Farahmand
Responsible Party
Sponsor Investigator
Principal Investigator

Amirhossein Farahmand

The effect of non-surgical periodontal therapy with adjunctive topical doxycycline gel on HbA1c in patients with type 2 diabetes mellitus (DM).

Islamic Azad University, Tehran

Eligibility Criteria

Inclusion Criteria

  • Patients with diabetes mellitus type II (at least 3 months before diagnosis, and A fasting blood sugar level of more than 125 mg/dl) and has periodontal disease is a chronic moderate (has a clinical attachment level of 3-4 mm) peritonitis
  • Minimum of 16 natural teeth, and no periodontal treatment in the prior 6 months, - Had a glycated α hemoglobin (HbA1c) value between 7- 9 percent at screening
  • Had reported no changes in diabetes medications within the last 3 months were in the care of a physician for their diabetes.

Exclusion Criteria

  • Pregnancy or lactation
  • History of allergy to drugs used in the study
  • Diabetes-related emergency within 30 days ago
  • Use of nonsteroidal anti-inflammatory drugs
  • Or taking low dose daily aspirin (75-325 mg)\\
  • Use of immunosuppressive medications; antibiotic use
  • Risk of bleeding complications
  • The type of disease periodontal (Aggressive)
  • A history of periodontal treatment in the previous 6 months
  • Orthodontic treatment

Arms & Interventions

doxycycline gel

Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe

Intervention: Doxycycline Group

placebo gel

placebo topical gel was put into the periodontal pocket using an insulin syringe

Intervention: placebo topical gel

Outcomes

Primary Outcomes

Periodontal pocket

Time Frame: 15 days

Periodontal probe

Secondary Outcomes

  • glycated hemoglobin (HbA1c)(3 months)

Similar Trials